Dr. Thomas P. Haverty is currently an independent consultant to the pharmaceutical industry. Most recently he was Vice President, Merck BioVentures and Early Biologics at Merck Research Laboratories (MRL), responsible for all clinical development of biosimilars and early development of novel biologics through proof of concept.
Prior to his tenure at Merck, he was Group Vice President of Global Clinical Research at the Schering-Plough Research Institute (SPRI). Dr. Haverty was also Co-Chairman Development Committee for Immunology and Oncology which governed the development of compounds in these areas. During his 11-year tenure at SPRI, Dr. Haverty had extensive involvement in all therapy areas leading to several approvals (biologics underlined): ASMANEX, BRIDION, CAELYX, CLARINEX, DULERA, ELONVA, NASONEX, NOXAFIL, PEG-INTRON/Rebetol, REMICADE, SAPHRIS, SIMPONI, SUBOXONE, TEMODAR, VICTRELIS, VYTORIN, ZETIA and ZOELY.
Formerly, Dr. Haverty spent nine years at the RW Johnson Pharmaceutical Research Institute (a subsidiary of Johnson and Johnson) most recently as Head, Medical Informatics in La Jolla, CA, a position he held since 1996. He developed a Medical Informatics Fellowship where Physicians searched large databases of unknown gene sequences and determined which genes would make good drug targets. Previously at Johnson and Johnson, Dr. Haverty was Senior Director and Therapeutic Area Head of Immune Response Modifiers in Raritan, NJ where he conducted Clinical Research using murine and humanized monoclonal antibodies in Transplantation, Autoimmunity and Cancer. He was responsible for the development of the first therapeutic monoclonal antibody ORTHOCLONE OKT3.
A native third generation Californian, Tom received his BS degree from Stanford, his MD degree from UC San Diego and completed his Residency in Internal Medicine and Fellowship in Renal Immunology at the Hospital of the University of Pennsylvania in Philadelphia.